Sai Life Sciences announces plans to double headcount and expand capabilities in Manchester, UK
AsiaNet 87821
MANCHESTER, England and HYDERABAD, India, Jan. 28, 2021/PRNewswire=KYODO JBN/--
Sai Life Sciences, one of India's fastest growing Contract Research,
Development & Manufacturing Organizations (
(CRDMOs), today announced plans to double its headcount and expand its suite of
technical capabilities at its Manchester site, a centre of excellence for API
process and analytical development serving an expanding list of global clients.
Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai
Life Sciences, said, "We are truly heartened by our customers' response to our
Manchester site. The site serves as a vital bridge to our pilot and
manufacturing facilities in India, enabling seamless integration with the rest
of our service offerings across the USA and India, spanning the drug discovery,
development, and commercialisation continuum. This expansion will further
enhance our ability to add value to the NCE pipelines of our customers."
The Sai Life Sciences' Manchester site (
became fully operational in August 2020, onboarded 24 members of staff and has
since delivered multiple projects involving complex chemistry. With a growing
interest from customers across the UK, Europe and US, the present expansion
involves an increase in capacity from 20 to 75 fume cupboards and an increase
in headcount from 24 to 50+ scientists. A further expansion will see the
addition of a GMP Kilo Lab later in 2021. The company has recently commenced
recruitment for multiple positions
(https://www.sailife.com/current-openings-in-manchester/?utm_source=pr&utm_mediu
m=web&utm_campaign=double-headcount-capabilities-expansion-uk) across API
process and analytical research & development, particle sciences and
engineering.
Located in the heart of the Alderley Park life-sciences ecosystem, Sai Life
Sciences' Manchester site creates opportunities for UK and EU based pharma
companies and biotechs to have easier face-to-face collaboration with its
scientists, and to provide easier collaboration with US based clients due to
reduced time zone differences. The centre of excellence is well-positioned to
provide world-class development, scale-up and technology transfer to the Indian
sites as and when required. This new expansion will also add capability in
several key areas including process analytical technology (PAT),
crystallisation development and physical properties analysis.
Sai Life Sciences is currently amid an organization-wide transformation. It
is investing US$150 million during 2019-23, as part of the Sai Nxt (
initiative, across three core areas – people & culture, processes & automation,
infrastructure & scientific capabilities.
About Sai Life Sciences
Sai Life Sciences is a full-service CRO/ CDMO (
driven by a vision to support the launch of 25 new medicines by 2025. It works
with innovator pharma and biotech companies globally, accelerating the
discovery, development, and manufacture of complex small molecules. As a
pure-play CRO-CDMO, Sai Life Sciences has served diverse NCE development
programs, consistently delivering value based on its quality and
responsiveness. Today, it works with 7 of the top 10 large pharma companies, as
well as several small and mid-sized pharma & biotech companies. Sai Life
Sciences is privately held and backed by global investors, TPG Capital and HBM
Healthcare Investments. www.sailife.com
Photo:
https://mma.prnewswire.com/media/1428651/Sai_Life_Sciences_UK_Expansion.jpg
Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg
Source: Sai Life Sciences
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
